RhumbLine Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.34M | Buy |
57,650
+5,968
| +12% | +$242K | ﹤0.01% | 1805 |
|
|
2025
Q1 | $2.65M | Buy |
51,682
+2,148
| +4% | +$110K | ﹤0.01% | 1671 |
|
|
2024
Q4 | $2.74M | Buy |
49,534
+1,019
| +2% | +$56.4K | ﹤0.01% | 1721 |
|
|
2024
Q3 | $1.6M | Sell |
48,515
-1,145
| -2% | -$37.7K | ﹤0.01% | 2025 |
|
|
2024
Q2 | $1.35M | Buy |
49,660
+6,070
| +14% | +$165K | ﹤0.01% | 2084 |
|
|
2024
Q1 | $1.58M | Buy |
43,590
+1,970
| +5% | +$71.6K | ﹤0.01% | 2020 |
|
|
2023
Q4 | $843K | Buy |
41,620
+5,614
| +16% | +$114K | ﹤0.01% | 2354 |
|
|
2023
Q3 | $640K | Buy |
36,006
+544
| +2% | +$9.67K | ﹤0.01% | 2459 |
|
|
2023
Q2 | $641K | Buy |
35,462
+6,944
| +24% | +$125K | ﹤0.01% | 2536 |
|
|
2023
Q1 | $358K | Buy |
28,518
+924
| +3% | +$11.6K | ﹤0.01% | 2559 |
|
|
2022
Q4 | $405K | Buy |
27,594
+296
| +1% | +$4.34K | ﹤0.01% | 2562 |
|
|
2022
Q3 | $467K | Buy |
27,298
+1,536
| +6% | +$26.3K | ﹤0.01% | 2528 |
|
|
2022
Q2 | $376K | Buy |
+25,762
| New | +$376K | ﹤0.01% | 2635 |
|